… Aspects of this heterogeneity have been implicated in tumour evolution, metastasis and
acquired therapeutic resistance. Although clinical progress in SCLC treatment has been …

… -related adverse effects in patients with non–small cell lung … immune-related adverse effects
and treatment efficacy. This … inhibitor therapy, T cells recognizing shared lung tumor and skin …

… derivatives to the anti-cancer repertoire following the entry of … administration, and some
side effects such as peripheral … side effects and improved drug delivery capacity for cancer …

… In lung cancers, the type of mutated oncogene and the cells of origin dictate LUAD versus
LUSC formation, tumor aggressiveness, and invasive capacity. Recent studies have identified …

… human non-small-cell lung cancer (NSCLC) cells. We showed that treatment with THZ1 (10−…
low-dose THZ1 might be tolerated better and lead to fewer negative effects in normal cells. …

… We extracted exosomes from normal and lung cancer cells via ultracentrifugation and then
observed … and found that miR-326 expression was negatively regulated by circSATB2. As a …

… cell lung carcinoma cells (H1299, p53-negative) in order to examine their response to IR and
combined treatment … with the aim of the radiosensitization of cancer cells. For example, CQ …

… -L1), an inhibitory ligand that negatively regulates T cell activation and proliferation by binding
to … that atezolizumab monotherapy had acceptable side effects with promising durability of …

… cell-intrinsic and non-cell-autonomous cancer hallmarks. In this Review, we discuss the impact
… vulnerabilities of non-small-cell lung cancer and assess the challenges and opportunities …

… ≥ 50% or tumor infiltrating immune cells ≥ 10%, compared … with PD-L1 tumor cells ≥ 5%
or tumor infiltrating immune cells ≥ 5% [… Grade 3 or 4 treatment-related adverse effects were …